Evidence map›Paper›PMID 39102302›Full record

ArticleJournal of the American Society of Nephrology : JASN2024

Poised for Innovation: Considerations for End Points for New Drug Development in Kidney Transplantation.

Roslyn B Mannon, Flavio G Vincenti

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Roslyn B MannonDivision of Nephrology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0003-1776-3680
Flavio G VincentiDepartment of Medicine and Surgery, University of California at San Francisco, San Francisco, California.ORCID 0000-0002-6701-4680

Funding

Novel Therapies to Modulate the Inflammatory Alloresponse in Renal GraftsU01AI113362 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VINCENTI, FLAVIO · 2014 to 2023
$15.2M
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical CenterU01DK115997 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Gaurav Agarwal, ROSLYN B MANNON · 2017 to 2026
$2.4M
An Exploratory Investigation of the Safety of Empagliflozin in Kidney Transplant Recipients (SEKTR)I01CX002666 · VA · OMAHA VA MEDICAL CENTER · PI ROSLYN B MANNON · 2024 to 2026
–
CSRD VA I01 CX002666NIAID NIH HHS U01 AI113362NIDDK NIH HHS U01 DK115997NIDDK NIH HHS U01DK115997NIH HHS U01AI113362U.S. Department of Veterans Affairs I01CX002666US Department of Veterans Affairs I01CX002666
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39102302
PMCPMC11543003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.